Boku Narikazu

Switching from <scp>FOLFIRI</scp> plus cetuximab to <scp>FOLFIRI</scp> plus bevacizumab based on early tumor shrinkage in <scp>RAS</scp> wild‐type metastatic colorectal cancer: A phase <scp>II</scp> trial (<scp>HYBRID</scp>) 

Cancer Medicine, 13(7), Apr 9, 2024  

Risk factors for abdominal surgical infectious complications after distal gastrectomy for gastric cancer: A post-hoc analysis of a randomized controlled trial (JCOG0912). 

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 50(3) 107982-107982, Jan 24, 2024  

Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). 

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, Jan 19, 2024  

Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). 

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, Jan 5, 2024  

5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer. 

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, Nov 21, 2023  

Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). 

Japanese journal of clinical oncology, Nov 10, 2023  

Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): a study protocol. 

BMC cancer, 23(1) 987-987, Oct 17, 2023  

Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer. 

Future oncology (London, England), 19(32) 2147-2155, Oct, 2023  

FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. 

Anticancer research, 43(9) 4115-4123, Sep, 2023  

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer. 

Translational oncology, 35 101718-101718, Sep, 2023  

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G) 

BMC Cancer, 23(1), Aug 5, 2023  

Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study. 

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 26(4) 614-625, Jul, 2023  

[Therapeutic Strategies Targeting HER2 for Gastric Cancer]. 

Gan to kagaku ryoho. Cancer & chemotherapy, 50(7) 756-762, Jul, 2023  

A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial 

Targeted Oncology, May 6, 2023  

Role of reduction gastrectomy in patients with gastric cancer with a single non‐curable factor: Supplementary analysis of <scp>REGATTA</scp> trial 

Annals of Gastroenterological Surgery, Apr 16, 2023  

周術期薬物療法の新しい展開 腎機能に基づくS-1用量算出式の有用性 JCOG1001副次解析 

日本胃癌学会総会記事, 95回 192-192, Feb, 2023  

周術期薬物療法の新しい展開 高度リンパ節転移を伴う進行胃癌に対する術前DOS療法の第II相試験(JCOG1704) 

日本胃癌学会総会記事, 95回 193-193, Feb, 2023  

Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study 

Gastric Cancer, Jan 25, 2023  

Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001). 

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 25(6) 1073-1081, Nov, 2022  

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. 

JAMA oncology, 8(10) 1447-1455, Oct 1, 2022  

ARHGAP-RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer. 

Oncogene, Sep 20, 2022  

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. 

BMJ open, 12(9) e063071, Sep 1, 2022  

Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). 

BMC gastroenterology, 22(1) 341-341, Jul 14, 2022  

Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials. 

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, Mar 31, 2022  Peer-reviewed

新規開発レジメンを用いた治療成績から考えた胃癌に有用なバイオマーカーとは HER2陽性胃癌に対するS-1/CDDP+/-trastuzumabによるネオアジュバント化学療法(JCOG1301C)(What is the useful biomarker for gastric cancer based on the therapeutic outcomes using the newly developed regimens? Neoadjuvant chemotherapy of S-1/CDDP +/- trastuzumab for HER2-positive gastric cancer(JCOG1301C)) 

日本胃癌学会総会記事, 94回 177-177, Mar, 2022  

Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer 

Scientific Reports, 12(1), Mar, 2022  Peer-reviewed

Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world. 

Journal of cancer research and clinical oncology, Feb 7, 2022  Peer-reviewed

Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part) 

Supportive Care in Cancer, 30(5) 4497-4504, Feb 3, 2022  

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study. 

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 25(1) 245-253, Jan, 2022  

Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study. 

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 25(1) 254-254, Jan, 2022  

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study 

BMC Cancer, 21(1), Dec, 2021  

Lymphocyte-to-C-Reactive Protein Ratio Is the Most Sensitive Inflammation-Based Prognostic Score in Patients With Unresectable Metastatic Colorectal Cancer. 

Diseases of the colon and rectum, 64(11) 1331-1341, Nov 1, 2021  

Comparison of model fit and discriminatory ability of M category as defined by the 7th and 8th editions of the tumor-node-metastasis classification of colorectal cancer and the 9th edition of the Japanese classification. 

Cancer medicine, 10(20) 6937-6946, Oct, 2021  

Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis. 

Diseases of the colon and rectum, 64(9) 1074-1082, Sep 1, 2021  

Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. 

Nature cancer, 2(9) 962-977, Sep, 2021  

Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial. 

Cancer reports (Hoboken, N.J.), e1507, Jul 29, 2021  Peer-reviewed